Cargando…

Contemporary oncology trials, drug approvals and the physician-patient relationship

Detalles Bibliográficos
Autores principales:	Schnog, John-John B., Samson, Michael J., Duits, Ashley J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904103/ https://www.ncbi.nlm.nih.gov/pubmed/36778936 http://dx.doi.org/10.1016/j.lana.2022.100247

Ejemplares similares

An urgent call to raise the bar in oncology
por: Schnog, John-John B., et al.
Publicado: (2021)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence
por: Abbasi, Haleema Qayyum, et al.
Publicado: (2023)

I-ACT for Children: helping close the gap in drug approval for adults and children
por: Coppes, Max J., et al.
Publicado: (2022)

Approved Societies and Hospital Treatment
por: Michelli, P. J.
Publicado: (1922)

Single-arm trials for domestic oncology drug approvals in China
por: Zhang, Hong, et al.
Publicado: (2023)

Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology
por: Kurtin, Sandra E., et al.
Publicado: (2020)

Hospitals and Approved Societies
por: Dunstan, S.
Publicado: (1923)

Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs
por: Sisa, Ivan, et al.
Publicado: (2021)

Regulatory approval of COVID-19 vaccine for restricted use in clinical trial mode
por: Mohapatra, Prasanta Raghab, et al.
Publicado: (2021)

Approved Societies and Hospital Treatment
por: Squires, F.
Publicado: (1922)

Approved Societies and Hospital Treatment
por: Squires, F.
Publicado: (1922)

Letter comments on: “Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’”
por: Müller, B., et al.
Publicado: (2022)

Efficacy of smallpox approved tecovirimat (Tpoxx) drug against Monkeypox: current update and futuristic prospects
por: Das, Tuyelee, et al.
Publicado: (2023)

Edinburgh Royal Infirmary and Approved Societies
por: Caw, Wm. S.
Publicado: (1922)

Section 12 approval: fit for purpose?
por: Gupta, Nidhi, et al.
Publicado: (2020)

Section 12 approval: fit for purpose?
por: Ballantyne-Watts, Darryl
Publicado: (2020)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Vaccine approval before phase 3 trial results: a consequence of vaccine access inequity
por: Núñez, Isaac
Publicado: (2022)

Cardio-Oncology and the Patient–Physician Relationship
por: Ky, Bonnie
Publicado: (2020)

Do the Approved Societies Seek to Control the Doctors?
por: Ward, Gordon
Publicado: (1922)

Research approvals iceberg: helping it melt away
por: Kolstoe, Simon E., et al.
Publicado: (2019)

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
por: Tateo, Valentina, et al.
Publicado: (2023)

Untoward global effects of current guideline formulation of stereotactic radiotherapy for symptomatic brain metastases by international medical societies
por: de Vocht, Dorien E.C.M., et al.
Publicado: (2023)

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021)

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients
por: Caldwell, Louise, et al.
Publicado: (2022)

Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs
por: Arora, Ankur, et al.
Publicado: (2017)

Ethical issues at the interface of clinical care and research practice in pediatric oncology: a narrative review of parents' and physicians' experiences
por: de Vries, Martine C, et al.
Publicado: (2011)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

Section 12(2) MHA approval process is fit for purpose
por: Khwaja, Masum
Publicado: (2020)

Contemporary Hematology/Oncology
por: Geary, C. G.
Publicado: (1980)

International oncology drug approvals for multiregional or single-country clinical trials: A systematic review
por: Zhang, Min, et al.
Publicado: (2022)

N-acetylcysteine reduces oxidative stress in sickle cell patients
por: Nur, Erfan, et al.
Publicado: (2012)

Measles: Contemporary considerations for the emergency physician
por: Blutinger, Erik, et al.
Publicado: (2023)

Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
por: Audibert, Céline, et al.
Publicado: (2016)

Contemporary Physicians of Texas
Publicado: (1889)

Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults
por: Lambert, David, et al.
Publicado: (2020)

Comment on: Patient physician communication
por: Jawad, Ali S M
Publicado: (2020)

Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?
por: Schuller, Yvonne, et al.
Publicado: (2018)

Very Important to Physicians
por: Foscue, G. B.
Publicado: (1908)

Cannot write session to /tmp/vufind_sessions/sess_ib3o993thso9oju620hhll5nir